Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

Summary

This study is an extension study to the Callisto protocol CP-106. Subjects must have completed all 12 treatment cycles of CP-106 without disease progression as per RECIST criteria,to be eligible to to be enrolled in this study. This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing) despite standard therapy (octreotide) or progression of neuroendocrine tumor(s).

Timeline

Start

2007-11

Primary completion

2010-03

Completion

2010-03

Drugs

Indications